Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

(2012) L.E. Nicolle et al.   CURRENT MEDICAL RESEARCH AND OPINION

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

(2011) Ian H. de Boer   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucose handling by the kidney

(2011) Amanda Mather et al.   KIDNEY INTERNATIONAL

Sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2010) Volker Vallon et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Pathologic Classification of Diabetic Nephropathy

(2010) T. W. C. Tervaert et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Renal glucose transporters: novel targets for hyperglycemia management

(2010) Amanda Mather et al.   Nature Reviews Nephrology